# Eversense® Non-adjunctive Use Post Approval Study

Study · id `cardio:ct-nct04836546` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04836546](<https://clinicaltrials.gov/study/NCT04836546>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04836546

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 925 participants.

## Technical summary

Registry record NCT04836546. Allocation not applicable; no masking; primary purpose other. Start 2021-04-13 (actual); primary completion 2026-03-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose other
- Phase: Not applicable
- Enrolled: 925 participants (planned count; ClinicalTrials.gov record NCT04836546, source copy `cardio:ctgov-nct04836546-2025-08-13`, retrieved 2026-10-26)
- Started: 2021-04-13 (actual) (ClinicalTrials.gov record NCT04836546, source copy `cardio:ctgov-nct04836546-2025-08-13`, retrieved 2026-10-26)
- Primary completion: 2026-03-31 (anticipated) (ClinicalTrials.gov record NCT04836546, source copy `cardio:ctgov-nct04836546-2025-08-13`, retrieved 2026-10-26)
- Completion: 2026-03-31 (anticipated) (ClinicalTrials.gov record NCT04836546, source copy `cardio:ctgov-nct04836546-2025-08-13`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04836546, source copy `cardio:ctgov-nct04836546-2025-08-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04836546-2025-08-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Eversense® Non-adjunctive Use Post Approval Study
- Acronym: NA-PAS
- Condition: Diabetes
- Intervention (Device): Blood glucose meter
- Intervention (Device): Eversense CGM System
- Lead sponsor: Senseonics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Senseonics, Inc. (`cardio:org-senseonics-inc`)

## Provenance

Content hash: 3b59c8f6652276e3bb22c79aca8f282052dc7dfced0d1e2ac631a3a1320c3f78
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
